{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:27:53Z","timestamp":1790666873642,"version":"4.1.0"},"reference-count":157,"publisher":"Portland Press Ltd.","issue":"10","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,5,31]]},"abstract":"<jats:p>All the components of the classic renin\u2013angiotensin system (RAS) have been identified in the brain. Today, the RAS is considered to be composed mainly of two axes: the pressor axis, represented by angiotensin (Ang) II\/angiotensin-converting enzyme\/AT1 receptors, and the depressor and protective one, represented by Ang-(1\u20137)\/ angiotensin-converting enzyme 2\/Mas receptors. Although the RAS exerts a pivotal role on electrolyte homeostasis and blood pressure regulation, their components are also implicated in higher brain functions, including cognition, memory, anxiety and depression, and several neurological disorders. Overactivity of the pressor axis of the RAS has been implicated in stroke and several brain disorders, such as cognitive impairment, dementia, and Alzheimer or Parkinson\u2019s disease. The present review is focused on the role of the protective axis of the RAS in brain disorders beyond its effects on blood pressure regulation. Furthermore, the use of drugs targeting centrally RAS and its beneficial effects on brain disorders are also discussed.<\/jats:p>","DOI":"10.1042\/cs20180189","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T15:40:13Z","timestamp":1527262813000},"page":"1021-1038","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The depressor axis of the renin\u2013angiotensin system and brain disorders: a translational approach"],"prefix":"10.1042","volume":"132","author":[{"given":"Mariela\u00a0M.","family":"Gironacci","sequence":"first","affiliation":[{"name":"Departamento de Qu\u00edmica Biol\u00f3gica, Facultad de Farmacia y Bioqu\u00edmica, Instituto de Qu\u00edmica y Fisicoqu\u00edmica Biol\u00f3gicas-CONICET, Universidad de Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Vicario","sequence":"additional","affiliation":[{"name":"Unidad Coraz\u00f3n-Cerebro, Servicio de Epidemiolog\u00eda y Prevenci\u00f3n Cardiovascular, Instituto Cardiovascular de Buenos Aires (ICBA), Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Cerezo","sequence":"additional","affiliation":[{"name":"Unidad Coraz\u00f3n-Cerebro, Servicio de Epidemiolog\u00eda y Prevenci\u00f3n Cardiovascular, Instituto Cardiovascular de Buenos Aires (ICBA), Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro\u00a0G.","family":"Silva","sequence":"additional","affiliation":[{"name":"Departamento de Qu\u00edmica Biol\u00f3gica, Facultad de Farmacia y Bioqu\u00edmica, Instituto de Qu\u00edmica y Fisicoqu\u00edmica Biol\u00f3gicas-CONICET, Universidad de Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2018,5,25]]},"reference":[{"key":"2021113011070074000_B1","article-title":"World Alzheimer Report 2014. Dementia and Risk Reduction: an Analysis of Protective and Modifiable Factors","author":"World Alzheimer Report","year":"2014"},{"key":"2021113011070074000_B2","article-title":"Depression and Other Common Mental Disorders: Global Health Estimates","author":"World Health Organization","year":"2017"},{"key":"2021113011070074000_B3","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1001\/jama.1995.03530230032026","article-title":"The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study","volume":"274","author":"Launer","year":"1995","journal-title":"J. Am. Med. Assoc."},{"key":"2021113011070074000_B4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S0140-6736(96)90608-X","article-title":"15-year longitudinal study of blood pressure and dementia","volume":"347","author":"Skoog","year":"1996","journal-title":"Lancet"},{"key":"2021113011070074000_B5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/01.HYP.31.3.780","article-title":"Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men","volume":"31","author":"Kilander","year":"1998","journal-title":"Hypertension"},{"key":"2021113011070074000_B6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7326\/0003-4819-137-3-200208060-00006","article-title":"Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease","volume":"137","author":"Kivipelto","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"2021113011070074000_B7","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1212\/01.wnl.0000345062.86148.3f","article-title":"Duration of antihypertensive drug use and risk of dementia: a prospective cohort study","volume":"72","author":"Haag","year":"2009","journal-title":"Neurology"},{"key":"2021113011070074000_B8","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1080\/14656566.2017.1333599","article-title":"Treatment options and considerations for hypertensive patients to prevent dementia","volume":"18","author":"Hernandorena","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"2021113011070074000_B9","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1357-2725(02)00306-0","article-title":"The brain renin-angiotensin system: location and physiological roles","volume":"35","author":"Mckinley","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021113011070074000_B10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00424-012-1102-2","article-title":"The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases","volume":"465","author":"Wright","year":"2013","journal-title":"Pflugers Arch."},{"key":"2021113011070074000_B11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1161\/HYPERTENSIONAHA.117.09167","article-title":"No brain renin-angiotensin system: deja vu all over again?","volume":"69","author":"Sigmund","year":"2017","journal-title":"Hypertension"},{"key":"2021113011070074000_B12","first-page":"67","article-title":"Brain renin-angiotensin system and dopaminergic cell vulnerability","volume":"8","author":"Labandeira-Garcia","year":"2014","journal-title":"Front. Neuroanat."},{"key":"2021113011070074000_B13","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/HYPERTENSIONAHA.116.08922","article-title":"Brain renin-angiotensin system: does it exist?","volume":"69","author":"Van Thiel","year":"2017","journal-title":"Hypertension"},{"key":"2021113011070074000_B14","first-page":"1","article-title":"Hypertension regulating angiotensin peptides in the pathobiology of cardiovascular disease","volume":"125","author":"Hussain","year":"2017","journal-title":"Clin. Exp. Hypertens."},{"key":"2021113011070074000_B15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","article-title":"The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases","volume":"125","author":"Li","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2021113011070074000_B16","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1161\/CIRCRESAHA.114.304975","article-title":"Response to letter regarding article, \u201cAT2 receptor activation induces natriuresis and lowers blood pressure\u201d","volume":"115","author":"Kemp","year":"2014","journal-title":"Circ. Res."},{"key":"2021113011070074000_B17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"2021113011070074000_B18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.regpep.2007.03.006","article-title":"Enzymatic pathways of the brain renin-angiotensin system: unsolved problems and continuing challenges","volume":"143","author":"Karamyan","year":"2007","journal-title":"Regul. Pept."},{"key":"2021113011070074000_B19","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1159\/000453172","article-title":"Effects of diabetic hyperglycemia on central Ang-(1-7)-Mas-R-nNOS pathways in spontaneously hypertensive rats","volume":"40","author":"Li","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"2021113011070074000_B20","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1007\/s12035-015-9260-9","article-title":"Angiotensin-(1-7) is reduced and inversely correlates with tau hyperphosphorylation in animal models of Alzheimer\u2019s disease","volume":"53","author":"Jiang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"2021113011070074000_B21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1161\/HYPERTENSIONAHA.113.01613","article-title":"Angiotensin II-independent angiotensin-(1-7) formation in rat hippocampus: involvement of thimet oligopeptidase","volume":"62","author":"Pereira","year":"2013","journal-title":"Hypertension"},{"key":"2021113011070074000_B22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.neuropharm.2015.12.026","article-title":"Increasing brain angiotensin converting enzyme 2 activity decreases anxiety-like behavior in male mice by activating central Mas receptors","volume":"105","author":"Wang","year":"2016","journal-title":"Neuropharmacology"},{"key":"2021113011070074000_B23","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1016\/0196-9781(88)90208-2","article-title":"Immunocytochemical localization of angiotensin-(1-7) in the rat forebrain","volume":"9","author":"Block","year":"1988","journal-title":"Peptides"},{"key":"2021113011070074000_B24","doi-asserted-by":"crossref","first-page":"16518","DOI":"10.1016\/S0021-9258(19)84737-3","article-title":"Identification of angiotensin-(1-7) in rat brain. Evidence for differential processing of angiotensin peptides","volume":"264","author":"Chappell","year":"1989","journal-title":"J. Biol. Chem."},{"key":"2021113011070074000_B25","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-017-0805-y","article-title":"Paracrine and intracrine angiotensin 1-7\/Mas receptor axis in the substantia nigra of rodents, monkeys, and humans","author":"Costa-Besada","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"2021113011070074000_B26","doi-asserted-by":"publisher","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113011070074000_B27","doi-asserted-by":"publisher","first-page":"H1416","DOI":"10.1152\/ajpheart.00141.2007","article-title":"Immunofluorescence localization of the receptor Mas in cardiovascular-related areas of the rat brain","volume":"293","author":"Becker","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011070074000_B28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00441-012-1354-3","article-title":"Immunohistochemical localization of the angiotensin-(1-7) receptor Mas in the murine forebrain","volume":"348","author":"Freund","year":"2012","journal-title":"Cell Tissue Res."},{"key":"2021113011070074000_B29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1113\/expphysiol.2011.058578","article-title":"Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke","volume":"96","author":"Mecca","year":"2011","journal-title":"Exp. Physiol."},{"key":"2021113011070074000_B30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/j.1471-4159.2011.07552.x","article-title":"Angiotensin-(1-7) through Mas receptor up-regulates neuronal norepinephrine transporter via Akt and Erk1\/2-dependent pathways","volume":"120","author":"Lopez Verrilli","year":"2012","journal-title":"J. Neurochem."},{"key":"2021113011070074000_B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20120652","article-title":"Neuromodulatory role of angiotensin-(1-7) in the central nervous system","volume":"125","author":"Gironacci","year":"2013","journal-title":"Clin. Sci."},{"key":"2021113011070074000_B32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.neuropharm.2013.03.025","article-title":"Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke","volume":"71","author":"Regenhardt","year":"2013","journal-title":"Neuropharmacology"},{"key":"2021113011070074000_B33","doi-asserted-by":"publisher","first-page":"R373","DOI":"10.1152\/ajpregu.00292.2006","article-title":"Differential expression of neuronal ACE2 in transgenic mice with overexpression of the brain renin-angiotensin system","volume":"292","author":"Doobay","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021113011070074000_B34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.npep.2013.09.002","article-title":"The expression of angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis are upregulated after acute cerebral ischemic stroke in rats","volume":"47","author":"Lu","year":"2013","journal-title":"Neuropeptides"},{"key":"2021113011070074000_B35","doi-asserted-by":"publisher","first-page":"7413963","DOI":"10.1155\/2016\/7413963","article-title":"Exercise training improves the altered renin-angiotensin system in the rostral ventrolateral medulla of hypertensive rats","volume":"2016","author":"Ren","year":"2016","journal-title":"Oxid. Med. Cell Longev."},{"key":"2021113011070074000_B36","doi-asserted-by":"publisher","first-page":"C420","DOI":"10.1152\/ajpcell.00409.2004","article-title":"Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes","volume":"290","author":"Gallagher","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2021113011070074000_B37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1161\/01.STR.0000127810.92616.78","article-title":"Dementia after stroke: the Framingham Study","volume":"35","author":"Ivan","year":"2004","journal-title":"Stroke"},{"key":"2021113011070074000_B38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.phrs.2017.06.017","article-title":"Beneficial effects of Angiotensin II receptor blockers in brain disorders","volume":"125","author":"Saavedra","year":"2017","journal-title":"Pharmacol. Res."},{"key":"2021113011070074000_B39","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13231-016-0022-1","article-title":"Therapeutic potential of the renin angiotensin system in ischaemic stroke","volume":"8","author":"Arroja","year":"2016","journal-title":"Exp. Transl. Stroke Med."},{"key":"2021113011070074000_B40","doi-asserted-by":"publisher","DOI":"10.1113\/EP086957","article-title":"Neuroprotection by post-stroke administration of an oral formulation of angiotensin-(1-7) in ischemic stroke","author":"Bennion","year":"2018","journal-title":"Exp. Physiol."},{"key":"2021113011070074000_B41","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.nbd.2014.08.005","article-title":"Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke","volume":"71","author":"Chang","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"2021113011070074000_B42","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1111\/j.1476-5381.2012.02105.x","article-title":"Suppressing inflammation by inhibiting the NF-kappaB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia","volume":"167","author":"Jiang","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"2021113011070074000_B43","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1113\/expphysiol.2013.075242","article-title":"Centrally administered angiotensin-(1-7) increases the survival of stroke-prone spontaneously hypertensive rats","volume":"99","author":"Regenhardt","year":"2014","journal-title":"Exp. Physiol."},{"key":"2021113011070074000_B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320316661060","article-title":"Serum activity of angiotensin converting enzyme 2 is decreased in patients with acute ischemic stroke","volume":"17","author":"Bennion","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"2021113011070074000_B45","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/ggi.12167","article-title":"Serum levels of renin-angiotensin system components in acute stroke patients","volume":"14","author":"Mogi","year":"2014","journal-title":"Geriatr. Gerontol. Int."},{"key":"2021113011070074000_B46","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/cns.12233","article-title":"Angiotensin converting enzyme 2\/Ang-(1-7)\/mas axis protects brain from ischemic injury with a tendency of age-dependence","volume":"20","author":"Zheng","year":"2014","journal-title":"CNS Neurosci. Ther."},{"key":"2021113011070074000_B47","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.neuropharm.2014.01.004","article-title":"Neuronal over-expression of ACE2 protects brain from ischemia-induced damage","volume":"79","author":"Chen","year":"2014","journal-title":"Neuropharmacology"},{"key":"2021113011070074000_B48","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.115.05185","article-title":"Activation of the neuroprotective angiotensin-converting enzyme 2 in rat ischemic stroke","volume":"66","author":"Bennion","year":"2015","journal-title":"Hypertension"},{"key":"2021113011070074000_B49","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.vph.2015.08.007","article-title":"Angiotensin-(1-7) counteracts the effects of Ang II on vascular smooth muscle cells, vascular remodeling and hemorrhagic stroke: Role of the NFsmall ka, CyrillicB inflammatory pathway","volume":"73","author":"Bihl","year":"2015","journal-title":"Vascul. Pharmacol."},{"key":"2021113011070074000_B50","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.arcmed.2007.07.010","article-title":"ACE2 overexpression inhibits angiotensin II-induced monocyte chemoattractant protein-1 expression in macrophages","volume":"39","author":"Guo","year":"2008","journal-title":"Arch. Med. Res."},{"key":"2021113011070074000_B51","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1111\/bph.12770","article-title":"Angiotensin-(1-7) induces cerebral ischaemic tolerance by promoting brain angiogenesis in a Mas\/eNOS-dependent pathway","volume":"171","author":"Jiang","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"2021113011070074000_B52","doi-asserted-by":"publisher","first-page":"H1598","DOI":"10.1152\/ajpheart.00490.2012","article-title":"The effects of hypertension on the cerebral circulation","volume":"304","author":"Pires","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011070074000_B53","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10571-015-0327-y","article-title":"Evidence to consider angiotensin ii receptor blockers for the treatment of early Alzheimer\u2019s disease","volume":"36","author":"Saavedra","year":"2016","journal-title":"Cell. Mol. Neurobiol."},{"key":"2021113011070074000_B54","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.brainres.2014.05.019","article-title":"Angiotensin-(1-7) improves cognitive function in rats with chronic cerebral hypoperfusion","volume":"1573","author":"Xie","year":"2014","journal-title":"Brain Res."},{"key":"2021113011070074000_B55","doi-asserted-by":"publisher","first-page":"16024","DOI":"10.1038\/npjamd.2016.24","article-title":"Deficiency of angiotensin-converting enzyme 2 causes deterioration of cognitive function","volume":"2","author":"Wang","year":"2016","journal-title":"NPJ Aging Mech. Dis."},{"key":"2021113011070074000_B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-017-0574-1","article-title":"Tau proteins and tauopathies in Alzheimer\u2019s disease","author":"Chong","year":"2018","journal-title":"Cell. Mol. Neurobiol."},{"key":"2021113011070074000_B57","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s40263-017-0483-3","article-title":"Targeting neuroinflammation to treat Alzheimer\u2019s disease","volume":"31","author":"Ardura-Fabregat","year":"2017","journal-title":"CNS Drugs"},{"key":"2021113011070074000_B58","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.tins.2009.07.006","article-title":"Angiotensins in Alzheimer\u2019s disease - friend or foe?","volume":"32","author":"Kehoe","year":"2009","journal-title":"Trends Neurosci."},{"key":"2021113011070074000_B59","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1021\/cn500363g","article-title":"The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future perspectives","volume":"6","author":"Kaur","year":"2015","journal-title":"ACS Chem. Neurosci."},{"key":"2021113011070074000_B60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1093\/ajh\/hpu197","article-title":"Neuroprotective effects of angiotensin receptor blockers","volume":"28","author":"Villapol","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"2021113011070074000_B61","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1016\/j.febslet.2012.09.004","article-title":"Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains","volume":"586","author":"Tian","year":"2012","journal-title":"FEBS Lett."},{"key":"2021113011070074000_B62","doi-asserted-by":"publisher","first-page":"e16037","DOI":"10.1371\/journal.pone.0016037","article-title":"Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats","volume":"6","author":"Zhu","year":"2011","journal-title":"PLoS One"},{"key":"2021113011070074000_B63","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/JAD-161265","article-title":"Angiotensin-III is increased in Alzheimer\u2019s disease in association with amyloid-beta and tau pathology","volume":"58","author":"Kehoe","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"2021113011070074000_B64","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/j.1471-4159.1982.tb07930.x","article-title":"Angiotensin converting enzyme in Alzheimer\u2019s disease increased activity in caudate nucleus and cortical areas","volume":"38","author":"Arregui","year":"1982","journal-title":"J. Neurochem."},{"key":"2021113011070074000_B65","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/0014-2999(91)90584-D","article-title":"Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer\u2019s disease","volume":"200","author":"Barnes","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011070074000_B66","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0197-4580(00)00259-1","article-title":"Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer\u2019s dementia","volume":"22","author":"Savaskan","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"2021113011070074000_B67","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1365-2990.2007.00885.x","article-title":"Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer\u2019s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy","volume":"34","author":"Miners","year":"2008","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"2021113011070074000_B68","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3233\/JAD-2011-101512","article-title":"Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer\u2019s disease","volume":"24","author":"Mateos","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"2021113011070074000_B69","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13195-016-0217-7","article-title":"Angiotensin-converting enzyme 2 is reduced in Alzheimer\u2019s disease in association with increasing amyloid-beta and tau pathology","volume":"8","author":"Kehoe","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"2021113011070074000_B70","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2174\/1567202613666160224124739","article-title":"Plasma angiotensin-(1-7) is a potential biomarker for Alzheimer\u2019s disease","volume":"13","author":"Jiang","year":"2016","journal-title":"Curr. Neurovasc. Res."},{"key":"2021113011070074000_B71","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/jnr.23404","article-title":"Conversion of Abeta43 to Abeta40 by the successive action of angiotensin-converting enzyme 2 and angiotensin-converting enzyme","volume":"92","author":"Liu","year":"2014","journal-title":"J. Neurosci. Res."},{"key":"2021113011070074000_B72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.neuroscience.2017.01.027","article-title":"Angiotensin-(1-7) administration attenuates Alzheimer\u2019s disease-like neuropathology in rats with streptozotocin-induced diabetes via Mas receptor activation","volume":"346","author":"Chen","year":"2017","journal-title":"Neuroscience"},{"key":"2021113011070074000_B73","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/nn.4086","article-title":"Mechanisms of stress in the brain","volume":"18","author":"Mcewen","year":"2015","journal-title":"Nat. Neurosci."},{"key":"2021113011070074000_B74","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.phrs.2013.07.004","article-title":"Angiotensin as stress mediator: role of its receptor and interrelationships among other stress mediators and receptors","volume":"76","author":"Bali","year":"2013","journal-title":"Pharmacol. Res."},{"key":"2021113011070074000_B75","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bbr.2017.05.026","article-title":"Reduced anxiety-like behavior in transgenic rats with chronically overproduction of angiotensin-(1-7): role of the Mas receptor","volume":"331","author":"Kangussu","year":"2017","journal-title":"Behav. Brain Res."},{"key":"2021113011070074000_B76","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/nn.4087","article-title":"Stress weakens prefrontal networks: molecular insults to higher cognition","volume":"18","author":"Arnsten","year":"2015","journal-title":"Nat. Neurosci."},{"key":"2021113011070074000_B77","doi-asserted-by":"publisher","first-page":"15009","DOI":"10.1523\/JNEUROSCI.0892-11.2011","article-title":"Blood-borne angiotensin II acts in the brain to influence behavioral and endocrine responses to psychogenic stress","volume":"31","author":"Krause","year":"2011","journal-title":"J. Neurosci."},{"key":"2021113011070074000_B78","doi-asserted-by":"publisher","first-page":"11867","DOI":"10.1074\/jbc.273.19.11867","article-title":"Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene","volume":"273","author":"Walther","year":"1998","journal-title":"J. Biol. Chem."},{"key":"2021113011070074000_B79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0166-4328(99)00115-1","article-title":"Sex specific behavioural alterations in Mas-deficient mice","volume":"107","author":"Walther","year":"2000","journal-title":"Behav. Brain Res."},{"key":"2021113011070074000_B80","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.jad.2012.07.024","article-title":"Angiotensin-(1-7) central administration induces anxiolytic-like effects in elevated plus maze and decreased oxidative stress in the amygdala","volume":"145","author":"Bild","year":"2013","journal-title":"J. Affect. Disord."},{"key":"2021113011070074000_B81","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bbr.2013.09.003","article-title":"Angiotensin-(1-7) attenuates the anxiety and depression-like behaviors in transgenic rats with low brain angiotensinogen","volume":"257","author":"Kangussu","year":"2013","journal-title":"Behav. Brain Res."},{"key":"2021113011070074000_B82","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1042\/CS20160116","article-title":"Anxiolytic- and antidepressant-like effects of angiotensin-(1-7) in hypertensive transgenic (mRen2)27 rats","volume":"130","author":"Almeida-Santos","year":"2016","journal-title":"Clin. Sci."},{"key":"2021113011070074000_B83","first-page":"1","article-title":"Behaviour of the transgenic (mREN2)27 rat","volume":"729","author":"Wilson","year":"1996","journal-title":"Brain Res."},{"key":"2021113011070074000_B84","doi-asserted-by":"publisher","first-page":"e5552","DOI":"10.1371\/journal.pone.0005552","article-title":"The association between hypertension and depression and anxiety disorders: results from a nationally-representative sample of South African adults","volume":"4","author":"Grimsrud","year":"2009","journal-title":"PLoS One"},{"key":"2021113011070074000_B85","first-page":"10","article-title":"Depression increases the risk for uncontrolled hypertension","volume":"18","author":"Rubio-Guerra","year":"2013","journal-title":"Exp. Clin. Cardiol."},{"key":"2021113011070074000_B86","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/jhh.2012.18","article-title":"Depression and anxiety are associated with a diagnosis of hypertension 5 years later in a cohort of late middle-aged men and women","volume":"27","author":"Ginty","year":"2013","journal-title":"J. Hum. Hypertens."},{"key":"2021113011070074000_B87","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/HJH.0000000000000850","article-title":"Comorbidity of depression and anxiety disorders in patients with hypertension","volume":"34","author":"Graham","year":"2016","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B88","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/HJH.0b013e32835080b7","article-title":"Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies","volume":"30","author":"Meng","year":"2012","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0014-2999(02)01283-9","article-title":"The role of angiotensin II in cognition and behaviour","volume":"438","author":"Gard","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"2021113011070074000_B90","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1517\/14728222.8.1.7","article-title":"Angiotensin as a target for the treatment of Alzheimer\u2019s disease, anxiety and depression","volume":"8","author":"Gard","year":"2004","journal-title":"Expert Opin. Ther. Targets"},{"key":"2021113011070074000_B91","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1097\/HJH.0000000000001030","article-title":"Depression, anxiety and risk of hypertension in mid-aged women: a prospective longitudinal study","volume":"34","author":"Jackson","year":"2016","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B92","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1515\/JBCPP.2003.14.4.323","article-title":"Captopril and enalapril improve cognition and depressed mood in hypertensive patients","volume":"14","author":"Braszko","year":"2003","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"2021113011070074000_B93","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10571-011-9656-7","article-title":"Lower frequency of antidepressant use in patients on renin-angiotensin-aldosterone system modifying medications","volume":"31","author":"Nasr","year":"2011","journal-title":"Cell. Mol. Neurobiol."},{"key":"2021113011070074000_B94","doi-asserted-by":"publisher","first-page":"849","DOI":"10.4088\/JCP.11m07316","article-title":"The renin-angiotensin pathway in posttraumatic stress disorder: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are associated with fewer traumatic stress symptoms","volume":"73","author":"Khoury","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"2021113011070074000_B95","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12916-017-0916-3","article-title":"The renin-angiotensin system: a possible new target for depression","volume":"15","author":"Vian","year":"2017","journal-title":"BMC Med."},{"key":"2021113011070074000_B96","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10654-011-9641-y","article-title":"Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway","volume":"27","author":"Johansen","year":"2012","journal-title":"Eur. J. Epidemiol."},{"key":"2021113011070074000_B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1470320316666750","article-title":"Renin-angiotensin system gene expression and neurodegenerative diseases","volume":"17","author":"Goldstein","year":"2016","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"2021113011070074000_B98","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/1352458508097923","article-title":"Angiotensin-converting enzyme (ACE) and ACE2 levels in the cerebrospinal fluid of patients with multiple sclerosis","volume":"15","author":"Kawajiri","year":"2009","journal-title":"Mult. Scler."},{"key":"2021113011070074000_B99","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(04)16305-8","article-title":"Parkinson\u2019s disease","volume":"363","author":"Samii","year":"2004","journal-title":"Lancet"},{"key":"2021113011070074000_B100","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jns.2016.07.031","article-title":"Peripheral levels of angiotensins are associated with depressive symptoms in Parkinson\u2019s disease","volume":"368","author":"Rocha","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"2021113011070074000_B101","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/j.1528-1167.2008.01581.x","article-title":"The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis","volume":"49","author":"Arganaraz","year":"2008","journal-title":"Epilepsia"},{"key":"2021113011070074000_B102","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1042\/CS20100053","article-title":"Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy","volume":"119","author":"Pereira","year":"2010","journal-title":"Clin. Sci."},{"key":"2021113011070074000_B103","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.neuint.2012.04.012","article-title":"The levels of renin-angiotensin related components are modified in the hippocampus of rats submitted to pilocarpine model of epilepsy","volume":"61","author":"Gouveia","year":"2012","journal-title":"Neurochem. Int."},{"key":"2021113011070074000_B104","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson\u2019s disease","volume":"26","author":"Perez-Lloret","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2021113011070074000_B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2017.12.027","article-title":"Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer\u2019s disease pathogenesis: potential strategies to protect the LC against aging","author":"Satoh","year":"2017","journal-title":"Brain Res."},{"key":"2021113011070074000_B106","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/aap.12019","article-title":"Noradrenaline transmission reducing drugs may protect against a broad range of diseases","volume":"34","author":"Fitzgerald","year":"2015","journal-title":"Auton. Autacoid Pharmacol."},{"key":"2021113011070074000_B107","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1161\/01.HYP.35.6.1248","article-title":"Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus","volume":"35","author":"Gironacci","year":"2000","journal-title":"Hypertension"},{"key":"2021113011070074000_B108","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.regpep.2003.10.026","article-title":"Angiotensin-(1-7) inhibits the angiotensin II-enhanced norepinephrine release in coarcted hypertensive rats","volume":"118","author":"Gironacci","year":"2004","journal-title":"Regul. Pept."},{"key":"2021113011070074000_B109","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1002\/glia.22716","article-title":"Myelination, oligodendrocytes, and serious mental illness","volume":"62","author":"Haroutunian","year":"2014","journal-title":"Glia"},{"key":"2021113011070074000_B110","doi-asserted-by":"publisher","first-page":"R1173","DOI":"10.1152\/ajpregu.00467.2015","article-title":"Angiotensin-(1-7) protects from brain damage induced by shiga toxin 2-producing enterohemorrhagic Escherichia coli","volume":"311","author":"Goldstein","year":"2016","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"2021113011070074000_B111","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"2021113011070074000_B112","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/bmj.324.7339.699","article-title":"Use of ramipril in preventing stroke: double blind randomised trial","volume":"324","author":"Bosch","year":"2002","journal-title":"Br. Med. J."},{"key":"2021113011070074000_B113","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahlof","year":"2002","journal-title":"Lancet"},{"key":"2021113011070074000_B114","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(01)06178-5","article-title":"Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack","volume":"358","year":"2001","journal-title":"Lancet"},{"key":"2021113011070074000_B115","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B116","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1161\/01.STR.0000075777.18006.89","article-title":"The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors","volume":"34","author":"Schrader","year":"2003","journal-title":"Stroke"},{"key":"2021113011070074000_B117","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ijcard.2016.04.096","article-title":"Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - a real-world population study in Taiwan","volume":"215","author":"Pai","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"2021113011070074000_B118","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.1997.03540340047031","article-title":"Brain infarction and the clinical expression of Alzheimer disease. The Nun Study","volume":"277","author":"Snowdon","year":"1997","journal-title":"J. Am. Med. Assoc."},{"key":"2021113011070074000_B119","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1357-2725(02)00273-X","article-title":"Bradykinin, angiotensin-(1-7), and ACE inhibitors: how do they interact?","volume":"35","author":"Tom","year":"2003","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2021113011070074000_B120","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s00441-006-0190-8","article-title":"The CNS renin-angiotensin system","volume":"326","author":"Von Bohlen Und Halbach","year":"2006","journal-title":"Cell Tissue Res."},{"key":"2021113011070074000_B121","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4103\/0022-3859.188553","article-title":"Can angiotensin-converting enzyme inhibitors impact cognitive decline in early stages of Alzheimer\u2019s disease? An overview of research evidence in the elderly patient population","volume":"62","author":"Rygiel","year":"2016","journal-title":"J. Postgrad. Med."},{"key":"2021113011070074000_B122","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","article-title":"Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis","volume":"31","author":"Levi Marpillat","year":"2013","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B123","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(98)03086-4","article-title":"Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial","volume":"352","author":"Forette","year":"1998","journal-title":"Lancet"},{"key":"2021113011070074000_B124","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"2021113011070074000_B125","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.113.00147","article-title":"Is hypertension associated with an accelerated aging of the brain?","volume":"63","author":"Tzourio","year":"2014","journal-title":"Hypertension"},{"key":"2021113011070074000_B126","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S1474-4422(08)70143-1","article-title":"Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial","volume":"7","author":"Peters","year":"2008","journal-title":"Lancet Neurol."},{"key":"2021113011070074000_B127","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson","year":"2011","journal-title":"Lancet Neurol."},{"key":"2021113011070074000_B128","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.jhh.1001964","article-title":"Effect of telmisartan\/hydrochlorothiazide vs lisinopril\/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients","volume":"20","author":"Fogari","year":"2006","journal-title":"J. Hum. Hypertens."},{"key":"2021113011070074000_B129","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/sj.jhh.1001613","article-title":"Influence of losartan and atenolol on memory function in very elderly hypertensive patients","volume":"17","author":"Fogari","year":"2003","journal-title":"J. Hum. Hypertens."},{"key":"2021113011070074000_B130","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00228-003-0717-9","article-title":"Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension","volume":"59","author":"Fogari","year":"2004","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"2021113011070074000_B131","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archinternmed.2011.1391","article-title":"Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial","volume":"172","author":"Hajjar","year":"2012","journal-title":"Arch. Intern. Med."},{"key":"2021113011070074000_B132","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1524-6175.2005.04498.x","article-title":"Hypertension and cognitive decline: impact on executive function","volume":"7","author":"Vicario","year":"2005","journal-title":"J. Clin. Hypertens."},{"key":"2021113011070074000_B133","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/VHRM.S18777","article-title":"Cognitive evolution in hypertensive patients: a six-year follow-up","volume":"7","author":"Vicario","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"2021113011070074000_B134","doi-asserted-by":"publisher","first-page":"783696","DOI":"10.1155\/2012\/783696","article-title":"Cognition and vascular risk factors: an epidemiological study","volume":"2012","author":"Vicario","year":"2012","journal-title":"Int. J. Hypertens."},{"key":"2021113011070074000_B135","doi-asserted-by":"publisher","DOI":"10.1016\/j.hipert.2018.01.004","article-title":"Neurocognitive disorder in hypertensive patients. Heart-Brain Study","author":"Vicario","year":"2018","journal-title":"Hipertens Riesgo. Vasc."},{"key":"2021113011070074000_B136","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1001\/archneurol.2012.1010","article-title":"Impact of Angiotensin receptor blockers on Alzheimer disease neuropathology in a large brain autopsy series","volume":"69","author":"Hajjar","year":"2012","journal-title":"Arch. Neurol."},{"key":"2021113011070074000_B137","doi-asserted-by":"publisher","first-page":"b5465","DOI":"10.1136\/bmj.b5465","article-title":"Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis","volume":"340","author":"Li","year":"2010","journal-title":"Br. Med. J."},{"key":"2021113011070074000_B138","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1097\/HJH.0000000000000086","article-title":"Angiotension receptor blockers reduce the risk of dementia","volume":"32","author":"Chiu","year":"2014","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B139","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jocn.2016.02.036","article-title":"The association of renin-angiotensin system blockade use with the risks of cognitive impairment of aging and Alzheimer\u2019s disease: a meta-analysis","volume":"33","author":"Zhuang","year":"2016","journal-title":"J. Clin. Neurosci."},{"key":"2021113011070074000_B140","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3233\/JAD-171119","article-title":"The coming of age of the angiotensin hypothesis in Alzheimer\u2019s disease: progress toward disease prevention and treatment?","volume":"62","author":"Kehoe","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"2021113011070074000_B141","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-170101","article-title":"The rationale and design of the reducing pathology in Alzheimer\u2019s disease through angiotensin TaRgeting (RADAR) trial","volume":"61","author":"Kehoe","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"2021113011070074000_B142","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3233\/JAD-161198","article-title":"Rationale and design of the mechanistic potential of antihypertensives in preclinical Alzheimer\u2019s (HEART) trial","volume":"61","author":"Wharton","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"2021113011070074000_B143","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/archinternmed.2009.175","article-title":"Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study","volume":"169","author":"Sink","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"2021113011070074000_B144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2013-002881","article-title":"Effects of centrally acting ACE inhibitors on the rate of cognitive decline in dementia","volume":"3","author":"Gao","year":"2013","journal-title":"BMJ Open"},{"key":"2021113011070074000_B145","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2174\/1567205014666171016101816","article-title":"Pharmacogenetics of angiotensin-converting enzyme inhibitors in patients with Alzheimer\u2019s disease dementia","volume":"15","author":"De Oliveira","year":"2018","journal-title":"Curr. Alzheimer. Res."},{"key":"2021113011070074000_B146","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1212\/01.WNL.0000140705.23869.E9","article-title":"Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression","volume":"63","author":"Ohrui","year":"2004","journal-title":"Neurology"},{"key":"2021113011070074000_B147","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13195-017-0255-9","article-title":"Memory is preserved in older adults taking AT1 receptor blockers","volume":"9","author":"Ho","year":"2017","journal-title":"Alzheimers Res. Ther."},{"key":"2021113011070074000_B148","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/0196-9781(93)90063-M","article-title":"Angiotensin(1-7) in the spontaneously hypertensive rat","volume":"14","author":"Kohara","year":"1993","journal-title":"Peptides"},{"key":"2021113011070074000_B149","first-page":"R1273","article-title":"Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene","volume":"266","author":"Moriguchi","year":"1994","journal-title":"Am. J. Physiol."},{"key":"2021113011070074000_B150","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"2021113011070074000_B151","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/01.HYP.0000124667.34652.1a","article-title":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors","volume":"43","author":"Ishiyama","year":"2004","journal-title":"Hypertension"},{"key":"2021113011070074000_B152","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1093\/ajh\/hpu201","article-title":"Azilsartan is associated with increased circulating angiotensin-(1-7) levels and reduced renovascular 20-HETE levels","volume":"28","author":"Carroll","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"2021113011070074000_B153","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1097\/00004872-199606000-00017","article-title":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension","volume":"14","author":"Luque","year":"1996","journal-title":"J. Hypertens."},{"key":"2021113011070074000_B154","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/01.CIR.0000153269.07762.3B","article-title":"Losartan increases bradykinin levels in hypertensive humans","volume":"111","author":"Campbell","year":"2005","journal-title":"Circulation"},{"key":"2021113011070074000_B155","doi-asserted-by":"publisher","first-page":"H2281","DOI":"10.1152\/ajpheart.00618.2005","article-title":"Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function","volume":"289","author":"Ferrario","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2021113011070074000_B156","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1161\/01.HYP.31.2.699","article-title":"Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan","volume":"31","author":"Iyer","year":"1998","journal-title":"Hypertension"},{"key":"2021113011070074000_B157","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.regpep.2007.08.001","article-title":"Involvement of angiotensin-(1-7) in the hypothalamic hypotensive effect of captopril in sinoaortic denervated rats","volume":"146","author":"Hocht","year":"2008","journal-title":"Regul. Pept."}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/10\/1021\/449164\/cs-2018-0189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/132\/10\/1021\/449164\/cs-2018-0189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T12:04:14Z","timestamp":1638273854000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/132\/10\/1021\/77789\/The-depressor-axis-of-the-renin-angiotensin-system"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,25]]},"references-count":157,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,5,31]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20180189","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,25]]}}}